Home · Health · Nov 9 archive
FDA Mandates Warning Labels for GLP-1 Drugs Over Rare Eye Condition Risk
· Confirmed
In Short: The FDA has required drugmakers to add warnings about a rare eye condition to the labels of GLP-1 drugs, including popular obesity treatments like Ozempic and Wegovy.
The Food and Drug Administration (FDA) has mandated that manufacturers of GLP-1 receptor agonist drugs, including popular obesity treatments like Ozempic, Wegovy, Zepbound, and Mounjaro, must now include a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) on their drug labels.
NAION, sometimes referred to as an 'eye stroke,' is caused by insufficient blood flow to the optic nerve and can lead to permanent vision loss. The FDA's decision comes after identifying 15 probable NAION cases in clinical trials, with 10 occurring in patients taking GLP-1 drugs, five in those receiving a placebo, and none in patients on non-GLP-1 drugs.
According to the FDA, NAION is a very rare side effect of semaglutide, potentially affecting up to one in 10,000 people taking the drug. The condition is rare overall, occurring in between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmologists.
In May, the American Academy of Ophthalmologists and the American Diabetes Association published a joint consensus statement recommending 'shared decision-making between the patient and their care team' on whether to start, continue, or discontinue taking a GLP-1 drug if NAION develops or if a patient is at higher risk. The FDA's stance is broadly consistent with this recommendation.
The FDA advises that healthcare providers consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk. However, the FDA also emphasized that patients should not stop these medications out of undue concern.
The FDA's meta-analysis of 126 clinical trials, including a total of 134,253 participants, of whom 78,217 received a GLP-1 medication, identified a total of 15 probable NAION events. This underscores the rarity of the condition but highlights the need for caution and informed decision-making.
Background
The FDA has required drugmakers to add warnings about a potential increased risk of NAION, a rare eye condition, to the labels of all GLP-1 drugs.
What's confirmed
- The Food and Drug Administration (FDA) has mandated that manufacturers of GLP-1 receptor agonist drugs, including popular obesity treatments like Ozempic, Wegovy, Zepbound, and Mounjaro, must now include a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) on their drug labels.
- NAION, sometimes referred to as an 'eye stroke,' is caused by insufficient blood flow to the optic nerve and can lead to permanent vision loss. The FDA's decision comes after identifying 15 probable NAION cases in clinical trials, with 10 occurring in patients taking GLP-1 drugs, five in those receiving a placebo, and none in patients on non-GLP-1 drugs.
- According to the FDA, NAION is a very rare side effect of semaglutide, potentially affecting up to one in 10,000 people taking the drug. The condition is rare overall, occurring in between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmologists.
- In May, the American Academy of Ophthalmologists and the American Diabetes Association published a joint consensus statement recommending 'shared decision-making between the patient and their care team' on whether to start, continue, or discontinue taking a GLP-1 drug if NAION develops or if a patient is at higher risk. The FDA's stance is broadly consistent with this recommendation.
- The FDA advises that healthcare providers consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk. However, the FDA also emphasized that patients should not stop these medications out of undue concern.
- The FDA's meta-analysis of 126 clinical trials, including a total of 134,253 participants, of whom 78,217 received a GLP-1 medication, identified a total of 15 probable NAION events. This underscores the rarity of the condition but highlights the need for caution and informed decision-making.
What's still developing
- Test your knowledge with our new weekday mini crossword The Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk.
- In an interview with ABC News, Zelensky stressed that choosing national leaders belongs to Ukrainian society and that establishing safety conditions for voters requires an enforceable cessation of Russian bombardments.
- President Donald Trump is expected to announce the plans Tuesday at a campaign rally in Texas, The New York Times, The Washington Post and The Hill reported citing unnamed sources speaking on condition of anonymity.
- Multiple bills have been filed to hold state prisons to the same standard and to force the state to air condition its entire prison system by 2029, but all have died in the state Senate due to the high cost.
- State law requires county jails to be kept between 65 and 85 degrees.
- Out of 104 state prisons, 38 are fully air-conditioned.
- According to AARP, in 2025, an estimated 63 million Americans cared for adults or children with a medical condition or disability.
- (OSV News) — As Pope Leo XIV undergoes surgery for a lung nodule, medical experts consulted by OSV News said the condition is typically benign — but requires careful scrutiny and early intervention to address any possible cancer.
- People with ADHD had a 70 percent higher hazard of death from any cause than people without the condition.
- Those with a history of the condition are at increased risk of recurrence, including in the other eye, FDA said.
Sources
- Ars Technicalink
- NBC Newslink
- STATlink
- Gadgetreviewlink
- Kyivpostlink
- Emalink
- Pymntslink
- Upilink
- Kltvlink
- WIREDlink
- OSV Newslink
- ScienceAlertlink
- Medscapelink
- WarpBeat — background on FDA Warns GLP-1 Drugs May Cause Rare Eye Condition link
- TODAY — video link
- WBIR Channel 10 — video link
- NBC News — video link
- FOX 5 New York — video link
- FOX 9 Minneapolis-St. Paul — video link
- WTHR — video link